retatrutide mechanism glp-1 gip glucagon triple agonist Retatrutide—A Game Changer in Obesity Pharmacotherapy Retatrutide Peptide | Advanced Weight
Description
In a 16-week trial, liraglutide was found to reduce the expressed desire for palatable taste properties, including sweet, fatty, salty, and savory flavors in individuals with obesity (Kadouh et al., 2020)
Miyamoto Y, Banno Y, Yamashita T, Fujimoto T, Oi S, Moritoh Y, et al
doi:10.2174/1381612825666190206105232 13
however, uncertainty persists due to heterogeneity in study design, outcome definitions, and follow-up duration
95% CI, 1.822.93
If patient cannot tolerate 3 mg dose, discontinue Saxenda
